|Day Low/High||13.55 / 14.13|
|52 Wk Low/High||11.30 / 27.50|
RICHMOND, Calif., Sept.
Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
You don't have to be Sigmund Freud to understand the psychology here.
I expect CRM to regain its footing quickly and challenge highs again soon.
If estimates continue to come up there will be institutional interest in the stock.
Apple in particular is helping the bullish cause.
Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A
RICHMOND, Calif., Aug.
RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.
Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment
Investors in Sangamo Therapeutics Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new September 21st contracts and identified one put and one call contract of particular interest.
RICHMOND, Calif., July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.
The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development
RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.
RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.
Sentiment is very positive, regardless of what the indices may say.
RICHMOND, Calif., June 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.
There is no question that we are becoming extended and ripe for some profit taking.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.